Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome.

Product information

CAS Number: 195615-83-9

Molecular Weight: 281.39

Formula: C19H23NO

Chemical Name: [(2,2-diphenyloxolan-3-yl)methyl]dimethylamine

Smiles: CN(C)CC1CCOC1(C1C=CC=CC=1)C1C=CC=CC=1

InChiKey: BOTHKNZTGGXFEQ-UHFFFAOYSA-N

InChi: InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice.

References:

1. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.

Products are for research use only. Not for human use.